Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GlucoTrack Inc (GCTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: GCTK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -12.96% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.72M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.19 | 52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 |
52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3442.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -161.01% | Return on Equity (TTM) -694.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5064418 | Price to Sales(TTM) - |
Enterprise Value -5064418 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.01 | Shares Outstanding 567456 | Shares Floating 428235 |
Shares Outstanding 567456 | Shares Floating 428235 | ||
Percent Insiders 8.84 | Percent Institutions 1.27 |
Upturn AI SWOT
GlucoTrack Inc
Company Overview
History and Background
GlucoTrack Inc. is a medical device company focused on developing, manufacturing, and commercializing innovative glucose monitoring solutions for people with diabetes and pre-diabetes. The company's aim is to provide continuous, non-invasive glucose monitoring to improve diabetes management and quality of life.
Core Business Areas
- Glucose Monitoring Systems: Develops and markets non-invasive glucose monitoring devices, primarily focusing on the GlucoTrack model.
- Related Consumables: Sells consumables required for the operation of the GlucoTrack device, such as ear clips.
Leadership and Structure
Information regarding leadership and structure specific to GlucoTrack Inc. is limited due to the company being privately held.
Top Products and Market Share
Key Offerings
- GlucoTrack Model: A non-invasive glucose monitoring device that uses a clip attached to the earlobe. This device measures glucose levels painlessly and continuously and displays the results on a small handheld device. Market share is minimal compared to traditional blood glucose meters and continuous glucose monitoring (CGM) systems. Competitors include Dexcom (DXCM) and Abbott (ABT) in the CGM market, and various manufacturers of blood glucose meters.
Market Dynamics
Industry Overview
The glucose monitoring market is driven by the increasing prevalence of diabetes globally. There is a growing demand for continuous and non-invasive monitoring solutions, although traditional finger-prick blood glucose meters still dominate.
Positioning
GlucoTrack is positioned as a niche player within the glucose monitoring market, focusing on the non-invasive segment. Its competitive advantage lies in its pain-free measurement approach, but it faces challenges from established CGM players like Dexcom and Abbott, which offer advanced features and proven accuracy.
Total Addressable Market (TAM)
The global diabetes care devices market is projected to reach hundreds of billions of dollars. GlucoTrack targets a subset of this market focused on non-invasive glucose monitoring. The exact percentage of TAM targeted by GlucoTrack is unknown, but their positioning will lead to only a small fraction of the total.
Upturn SWOT Analysis
Strengths
- Non-invasive glucose measurement technology
- Potential for improved patient comfort and compliance
- Addresses the needs of patients averse to needles
Weaknesses
- Limited clinical validation compared to established CGMs
- Potentially higher cost per reading compared to traditional methods
- Accuracy concerns relative to gold-standard glucose measurements
Opportunities
- Expanding into emerging markets with high diabetes prevalence
- Developing next-generation non-invasive glucose monitoring devices
- Partnering with diabetes management platforms and telehealth providers
Threats
- Intense competition from established CGM manufacturers
- Regulatory hurdles for new medical devices
- Changing reimbursement landscape for diabetes care
Competitors and Market Share
Key Competitors
- DXCM
- ABT
Competitive Landscape
GlucoTrack's main advantage is non-invasive technology. However, major players Dexcom and Abbott dominate the market, so the advantage needs to be more prominent.
Growth Trajectory and Initiatives
Historical Growth: Information on the company's historical growth isn't available because it's private.
Future Projections: Future projections aren't available because it is a private company.
Recent Initiatives: This information isn't available because the company is private.
Summary
GlucoTrack Inc. aims to revolutionize glucose monitoring with non-invasive technology. However, the company faces intense competition from established giants like Dexcom and Abbott in the CGM market. While non-invasive monitoring offers a unique appeal, the company must address concerns of accuracy, cost, and clinical validation. Securing partnerships, expanding market reach, and continuous innovation are crucial for the company's sustainability and growth in the long run.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Market research reports
- Industry publications
- Analyst reports
Disclaimers:
The information provided is based on available public sources and may not be fully comprehensive. Market share estimates are approximate. AI Rating generated based on available data and should not be taken as financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlucoTrack Inc
Exchange NASDAQ | Headquaters Rutherford, NJ, United States | ||
IPO Launch date 2013-04-25 | CEO, President & Director Mr. Paul V. Goode Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 11 | Website https://glucotrack.com |
Full time employees 11 | Website https://glucotrack.com | ||
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.